Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase I/II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Outcome
Results posted; single-arm, no comparison
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
May 2008
Ended
29 March 2019
Enrollment
43 participants
Sites
3
Primary outcomes
Response Rate
Sponsor type
Academic / other
Results posted
9 July 2020
Last update
9 July 2020

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 9 July 2020
Primary outcome
Response RateTemozolomide and Everolimus: 16 of 40Values: ParticipantsTime frame: 2 yearsNo analysis posted for this outcome (outcome 1)
Participants
Temozolomide and Everolimus: 43 started, 43 completed
Serious adverse events
Temozolomide and Everolimus: 15 of 43Participants with at least one serious adverse event, of those at risk, as posted
2 secondary outcomes
PFS · Progression-free Survival
Temozolomide and Everolimus 15.4 (9.4 to 20.4), n=43 [median months, 95% Confidence Interval]
To Determine the Safety and Tolerability of This Drug Combination.
Grade 3 or 4 Lymphopenia: Temozolomide and Everolimus 19/43 [Participants] (first of 6 rows)

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This research study will test the safety of RAD001 in combination with temozolomide.

Detailed description public domain (ClinicalTrials.gov)

* Participants will take RAD001 by mouth daily. They will also take temozolomide by mouth daily for one week, followed by a one-week break period. This one-week on/one week off schedule for temozolomide will continue for the duration of the treatment. * After the first month of treatment, there will be a 7-day observation period during which no study medication will be taken to observe for any side effects. * During all treatment cycles (1 cycle is 28 days in length) participants will have a physical exam and will be asked questions about their general health and specific questions about any problems they may be experiencing. Initially, participants will come in every other week. At each of these visits, blood work will be taken to monitor the participants health. * After every 2 months of treatment, participants will have a CT scan or MRI done to see how the medication is working.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Response Rate [2 years]. Count Of Participants, Participants. Temozolomide and Everolimus (n=40): 16.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression-free Survival [2 years]. Median, months (95% Confidence Interval). Temozolomide and Everolimus (n=43): 15.4 (9.4 to 20.4).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

To Determine the Safety and Tolerability of This Drug Combination. [2 years]. Count Of Participants, Participants. Grade 3 or 4 Lymphopenia: Temozolomide and Everolimus (n=43): 19. Grade 3 or 4 thrombocytopenia: Temozolomide and Everolimus (n=43): 7. Grade 3 or 4 mucositis: Temozolomide and Everolimus (n=43): 1. Grade 3 or 4 hyperglycemia: Temozolomide and Everolimus (n=43): 8. Grade 3 or 4 AST Increase: Temozolomide and Everolimus (n=43): 4. Grade 3 or 4 Leukocyte decrease: Temozolomide and Everolimus (n=43): 7.